Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068380 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00068380: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00068380 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068380, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well imatinib mesylate works in treating patients with refractory metastatic and/or unresectable stomach or gastroesophageal junction cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068380
The ClinicalTrials.gov registry entry for NCT00068380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00068380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068380 about?
NCT00068380 is a clinical study titled "A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer". Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well imatinib mesylate works in treating patients with refractory metastatic and/or unresectable stomach or gastroesophageal junction cancer.
What is the current status of trial NCT00068380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00068380?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00068380?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.